Phibro Animal Health Is Maintained at Underperform by B of A Securities
Phibro Animal Health Analyst Ratings
BofA Securities Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $15
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Maintains Target Price $13
Phibro Animal Health (PAHC) Receives a Sell From Barclays
BofA Securities Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $13
Phibro Animal Health Sell Rating: Concerns Over Operating Leverage and Profitability Despite Revenue Growth
Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Veeva Systems (VEEV)
Phibro Animal Health Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK), Phibro Animal Health (PAHC) and Amphastar Pharmaceuticals (AMPH)
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), BridgeBio Pharma (BBIO) and Phibro Animal Health (PAHC)
Underperform Rating for Phibro Animal Health: Analysis of Q1 Results and Future Challenges
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $16
Phibro Animal Health Analyst Ratings
Phibro Animal Health Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $17
Phibro Animal Health Analyst Ratings
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN) and Phibro Animal Health (PAHC)
Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Phibro Animal Health (PAHC) and Catalent (CTLT)